Coverage of the 2017 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Washington, DC, October 20-24, 2017.
Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.
Full coverage listing by topic
11/30/17
Coverage of the 2016 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Sunday, 20 November 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2016 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston, November 11-15, 2016.
Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.
Full coverage listing by topic
11/20/16
AASLD 2014: AbbVie Next-Generation Hepatitis C Drugs Promising in Early Studies
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 29 January 2015 00:00
- Written by Liz Highleyman
AbbVie's investigational HCV protease inhibitor ABT-493 and NS5A inhibitor ABT-530 demonstrated good antiviral activity in patients with genotype 1 chronic hepatitis C in a 3-day monotherapy study, as well as potent and synergistic activity against multiple HCV genotypes in laboratory replicon studies, according to presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting held recently in Boston.
Coverage of the 2015 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Monday, 23 November 2015 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2015 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in San Francisco, November 13-17, 2015.
Conference highlights include interferon-free therapy for hepatitis C, treatment for difficult-to-treat populations including people with HCV genotype 3 and liver cirrhosis, hepatitis B prevention and treatment, and management of advanced liver disease.
11/23/15
AASLD 2014: Experimental siRNA Therapy Lowers HBsAg Levels in Hepatitis B Patients
- Details
- Category: HBV Treatment
- Published on Tuesday, 23 December 2014 00:00
- Written by Liz Highleyman
ARC-520, a novel therapy using short interfering RNA, appeared safe and was associated with a reduction in hepatitis B surface antigen levels in chronic hepatitis B patients taking entecavir, according to Phase 2a study results reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in Boston.
More Articles...
- AASLD 2014: Entecavir and Tenofovir Work Well for People with Resistant Hepatitis B Virus
- AASLD 2014: Many Hepatitis C Patients with Cirrhosis or Advanced Fibrosis Face Liver Failure
- AASLD 2014: Sofosbuvir/ Ledipasvir Cures Most Previously Treated HCV Patients with Cirrhosis
- AASLD 2014: Screening Baby Boomers for HCV More Effective than Risk-based Testing
- Coverage of the 2014 AASLD Liver Meeting
- Coverage of the 2014 AASLD Liver Meeting
- AASLD 2014: AbbVie 3D Cures Recurrent HCV in Most Liver Transplant Recipients Without Cirrhosis
- AASLD 2014: DAAs Show Good Cure Rates and Liver Function Improvement for Transplant Recipients with Recurrent HCV
- AASLD 2014: Sofosbuvir/ Ledipasvir + Ribavirin Cures Most Post-Transplant HCV Recurrence
- AASLD 2014: Sofosbuvir + Simeprevir Shows Good Results in Real-World Use
- AASLD 2014: AbbVie 3D Regimen and Sofosbuvir/ Ribavirin Show High Cure Rates for HIV/HCV Coinfection
- AASLD 2014: Tenofovir Continues to Work Well Against Hepatitis B Virus for 8 Years
- AASLD 2014: Daclatasvir + Sofosbuvir Demonstrates Good Cure Rate for HCV Genotype 3 Patients
- AASLD 2014: Sofosbuvir + GS-5816 for 12 Weeks Shows High Cure Rates, 8 Weeks Less Effective
- AASLD 2014: Pegylated Interferon + Tenofovir Improves Odds of HBsAg Loss in Hepatitis B Patients
- AASLD 2014: Grazoprevir/ Elbasvir Combo Shows High Cure Rates, Including Cirrhotics and Coinfected
- AASLD 2014: Sofosbuvir/ Ledipasvir + Ribavirin Highly Effective for People with Decompensated Cirrhosis
- AASLD 2014: Sofosbuvir/Ledipasvir and AbbVie 2D Cure Most People with HCV Genotype 4
- AASLD 2014: Daclatasvir TRIO Regimen Has Good Cure Rates With or Without Cirrhosis
- AASLD 2014: Hepatitis B Testing and Treatment Rates Are Low Among U.S. Veterans
- AASLD 2014: Young Drug Injectors on Opioid Agonist Therapy Have Lower Risk of HCV Infection
- AASLD 2014: HIV Positive People Have High Survival Rates After Liver Transplants Due to HCC
- AASLD 2014: Sustained Response to HCV Treatment Reduces Mortality, Liver Cancer, Liver Transplants
- AASLD 2014: Sofosbuvir/Ledipasvir Cures Nearly All Genotype 1 HIV/HCV Coinfected Patients
- AASLD Liver Meeting Starts this Weekend in Boston
Web Design and Development by